Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 3, 2006, Pages 347-355

  Kimura, Shinya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bcr Abl; Cyclin dependent kinase; Hydrazine derivatives; Imatinib mesylate; SGX

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL; DRUG ANTAGONISM; GENETICS; HUMAN; PATENT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; PATENTS AS TOPIC; PROTEIN-TYROSINE KINASES;

EID: 39049107853     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206778776907     Document Type: Review

References (38)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40.
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-64.
4. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
5. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-71.
6. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
7. Gambacorti-Passerini C, Barni R, Le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCRABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-50.
8. Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002; 1587: 318-25.
9. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-8.
10. Hochhaus A, La Rosse P. Imatinib therapy in chronic myelogenous leukemia:strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-31.
11. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-78.
12. + leukemia activity of imatinib mesylate. Blood 2003; 102:2229-35.
13. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
14. O'Hara T, Pollock R, Stoffregen EP, et al. Inhibition of wildtype and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104: 2532-39.
15. Wolff NC, Veach DR, Tong WP, et al. PD166326, a novel tyrosine kinase inhibitor, has greater anti-leukemic activity than imatinib in a murine model of chronic myeloid leukemia. Blood 2005; 105: 3995-4003.
16. Golas JM, Arndt K, Etienne D, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 3: 375-81.
17. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-41.
18. Kimura S, Naito H, Segawa H, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948-54.
19. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATPcompetitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005; 102: 1992-97.
20. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10: 262-267.
21. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drugresistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102:11011-16.
22. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41.
23. Guihot F, Apperley JF, Shah N, et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: first results of the CA 180005 'START-A' study. Blood 2005; 106: 16a.
24. Talpaz M, Tousselot P, Kim DW, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia(CML) in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA 180006 'START-B' study. Blood 2005; 106: 16a.
25. Hochhaus A, Baccarani M, Sawyers C, et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA 180013 'START-C' phase II study. Blood 2005; 106: 17a.
26. + ALL) who are resistant or intolerant to imatinib: first results of the CA 180015 'START-L' study. Blood. 2005; 106: 17a.
27. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-51.
28. +ALL). Blood 2005; 106: 15a-16a.
29. Naito H, Kimura S, Nakaya Y, et al. in vivo Inhibitory effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on the proliferation of leukemic cells harbouring Abl kinase domain mutations. Leuk Res, in press.
30. + leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood, in press.
31. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006; 66: 1007-14.
32. O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 2005; 23: 329-36.
33. TM fragment-based lead discovery and structure-guided design to discovery of small molecule inhibitors of BCR-ABL tyrosine kinase active against the T315I imatinib-resistant mutant. Blood 2005; 106: 206a.
34. Arnold, D.W., Bounaud, P., Gosberg, A., Li, Z., Macdonald, I., Steensma, R.W., Wilson, M.E.: WO2006015123A1 (2006).
35. Caligiuri, M.G., Kley, N.A., Murthi, K.K.: WO2006002119A2 (2006).
36. Housey, G.M.: WO2005115992A1 (2005).
37. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukemia. Nature 2005; 435: 1267-70.
38. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714-9.